<DOC>
	<DOCNO>NCT02896907</DOCNO>
	<brief_summary>This pilot clinical trial study side effect ascorbic acid combination chemotherapy treat patient pancreatic cancer spread place body , come back , remove surgery . Nutrients find food dietary supplement , ascorbic acid , may improve tolerability chemotherapy regimen . Drugs use chemotherapy , fluorouracil , irinotecan hydrochloride , oxaliplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving ascorbic acid combination chemotherapy may work well treat patient pancreatic cancer .</brief_summary>
	<brief_title>Ascorbic Acid Combination Chemotherapy Treating Patients With Locally Advanced Recurrent Pancreatic Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety intravenous ascorbic acid combination fluorouracil , irinotecan hydrochloride , leucovorin calcium , oxaliplatin ( FOLFIRINOX ) define Common Terminology Criteria Adverse Events ( CTCAE ) version 4.03 patient advanced pancreatic cancer . SECONDARY OBJECTIVES : I . To test feasibility collect quality life ( QOL ) , patient report outcome ( PRO ) data correlative study patient advance pancreatic cancer .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Tetrahydrofolates</mesh_term>
	<mesh_term>Formyltetrahydrofolates</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Capable give informed consent Histological diagnosis adenocarcinoma pancreas Stage IV recurrent pancreatic cancer image Locally advance unresectable pancreatic cancer National Comprehensive Cancer Network ( NCCN ) criterion Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 No prior treatment metastatic disease ( prior neoadjuvant adjuvant chemotherapy , except FOLFIRINOX , chemoradiation radiation allow ) White blood count &gt; = 3000 Platelets &gt; = 100,000 Total bilirubin = &lt; 1.5 mg/dl Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 5 X upper limit normal ( ULN ) Creatinine &lt; 1.5 mg/dL Glucose6phosphatase deficiency ( G6PD ) level 514 units/g hemoglobin ( Hgb ) within institutional standard parameter All subject child produce potential must agree use contraception avoidance pregnancy measure enrol study Other pancreatic cancer histology ( islet cell , acinar , neuroendocrine tumor ) Resectable pancreatic cancer Prior neoadjuvant FOLFIRINOX Pregnant lactate female No clinical ascites ( mild ascites scan permissible ) Central nervous system ( CNS ) metastasis Known congestive heart failure , significant ventricular arrhythmia , cirrhosis , grade 4/5 chronic kidney disease , uncontrolled diabetes Active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy Peripheral neuropathy grade 2 great Any condition , psychiatric otherwise , would preclude informed consent , consistent followup compliance aspect study ( e.g. , untreated schizophrenia significant cognitive impairment , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>